Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections.
A vaccine against Pseudomonas aeruginosa based on recombinant outer membranes has been developed. After intramuscularly injecting into patients with severe burns, antibodies against P. aeruginosa were induced. Vaccination was well tolerated. Intranasal application of the vaccine into volunteers, induced specific s-IgA antibodies. We conclude that the newly developed vaccine may be suitable for protection of the main risk groups of P. aeruginosa infections. In particular, for the protection of burn patients and patients with cystic fibrosis.
Baumann
U
U
Medizinische Hochschule Hannover, Abteilung Pädiatrische Pneumonologie und Neonatalogie, 30623 Hannover, Germany.
Mansouri
E
E
von Specht
B-U
BU
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000032:analysis / Q000096:biosynthesis; D001426:Bacterial Proteins / Q000276:immunology*; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D002056:Burns / Q000150:complications; D004926:Escherichia coli / Q000378:metabolism; D005260:Female; D005822:Genetic Vectors; D006801:Humans; D007273:Injections, Intramuscular; D008074:Lipoproteins / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D018272:Porins / Q000276:immunology*; D011552:Pseudomonas Infections / Q000276:immunology* / Q000517:prevention & control*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D008074:Lipoproteins; D018272:Porins; D014614:Vaccines, Synthetic; C060507:outer membrane lipoprotein I, Bacteria